Chinook Therapeutics Insiders

KDNYDelisted Stock  USD 39.25  0.20  0.51%   
Chinook Therapeutics employs about 214 people. The company is managed by 10 executives with a total tenure of roughly 500 years, averaging almost 50.0 years of service per executive, having 21.4 employees per reported executive. Break down of Chinook Therapeutics' management performance can provide insight into the company performance.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Chinook Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5685) %, meaning that it created substantial loss on money invested by shareholders. Chinook Therapeutics' management efficiency ratios could be used to measure how well Chinook Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Chinook Therapeutics Workforce Comparison

Chinook Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 4,723. Chinook Therapeutics holds roughly 214 in number of employees claiming about 5% of equities under Health Care industry.

Chinook Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chinook Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chinook Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Chinook Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Chinook Therapeutics Notable Stakeholders

A Chinook Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Chinook Therapeutics often face trade-offs trying to please all of them. Chinook Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Chinook Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Tom FrohlichChief OfficerProfile
Jodi JamiesonVP HRProfile
MS MDSr StrategyProfile
Eric MBAChief OfficerProfile
Kirk JDSr CounselProfile
Alan MDEx OfficerProfile
Andrew DVMChief OfficerProfile
Eric JDCEO PresProfile
Noopur LiffickVP CommunicationsProfile
Delphine ImbertVP OperationsProfile

About Chinook Therapeutics Management Performance

The success or failure of an entity such as Chinook Therapeutics often depends on how effective the management is. Chinook Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Chinook management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Chinook management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. Chinook Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 138 people.
Please note, the imprecision that can be found in Chinook Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Chinook Therapeutics. Check Chinook Therapeutics' Beneish M Score to see the likelihood of Chinook Therapeutics' management manipulating its earnings.

Chinook Therapeutics Workforce Analysis

Traditionally, organizations such as Chinook Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Chinook Therapeutics within its industry.

Chinook Therapeutics Manpower Efficiency

Return on Chinook Therapeutics Manpower

Revenue Per Employee28.6K
Revenue Per Executive612.8K
Net Loss Per Employee877.9K
Net Loss Per Executive18.8M
Working Capital Per Employee1.6M
Working Capital Per Executive33.5M
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Consideration for investing in Chinook Stock

If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Bonds Directory
Find actively traded corporate debentures issued by US companies